Chewing Gum Containing Vitamin-c to Treat Emesis Gravidarum
Launched by MEDICAL UNIVERSITY OF VIENNA · Feb 23, 2020
Trial Information
Current as of August 22, 2025
Completed
Keywords
ClinConnect Summary
The following 3 groups of patients should be compared: (1) patients with emesis gravidarum who take a chewing gum with vitamin C (verum) "ad libitum" several times daily for 2 weeks; (2.) patients with emesis gravidarum who take chewing gum without vitamin C (placebo) "ad libitum" several times daily for 2 weeks; (3.) patients with emesis gravidarum who do not use chewing gum during the study phase. The enrollment will take place at the Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-Maternal Medicine, at the Medical University of Vienna. All pregnant women in the f...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • age ≥18 years
- • singleton pregnancy
- • signed information sheet
- • symptoms of nausea and / or vomiting in early pregnancy
- • no pre-existing medication for nausea and vomiting
- Exclusion criteria:
- • age \<18 years
- • multiple pregnancy
- • patients with gastric band or in Z.n. bariatric surgery
- • preexisting diabetes mellitus or gestational diabetes
- • inability to consent to participation in the study
- • already started therapy against the emesis gravidarum
- • taking any antiemetic drugs during the study phase
About Medical University Of Vienna
The Medical University of Vienna is a leading research institution dedicated to advancing healthcare through innovative clinical research and education. Renowned for its commitment to excellence in medical science, the university fosters interdisciplinary collaboration among researchers, clinicians, and academic professionals. Its clinical trials encompass a wide range of medical disciplines, aiming to develop cutting-edge therapies and improve patient outcomes. With state-of-the-art facilities and a strong emphasis on ethical standards, the Medical University of Vienna is at the forefront of transforming scientific discoveries into practical applications that enhance global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Patients applied
Trial Officials
Alex Farr, MD PhD
Principal Investigator
Medical University of Vienna, Department of Obstetrics and Gynecology; Vienna General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials